Rheumatoid Arthritis - Pipeline Review, H2 2013

08:32 EDT 5 Sep 2013 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Rheumatoid Arthritis - Pipeline Review, H2 2013 is a new report from Global Markets Direct published on 2013-08-29. This 392-page report is available in PDF from $2500.

Rheumatoid Arthritis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Rheumatoid Arthritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies mentioned:

Alcon, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
Antares Pharma, Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Inovio Biomedical Corporation
MedImmune LLC
Isis Pharmaceuticals, Inc.
Biotest AG
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Ablynx
Emergent BioSolutions Inc.
Novo Nordisk A/S
Infinity Pharmaceuticals, Inc.
Albany Molecular Research, Inc.
Plexxikon Inc.
ViaCord
arGentis Pharmaceuticals, LLC
Reliance Life Sciences Pvt. Ltd.
MediGene AG
Celltrion, Inc.
Table of Contents
Table of Contents 2
Introduction 10
Rheumatoid Arthritis Overview 11
Therapeutics Development 12
Rheumatoid Arthritis Therapeutics under Development by Companies 14
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 34
Mid Clinical Stage Products 35
Early Clinical Stage Products 36
Discovery and Pre-Clinical Stage Products 37
Rheumatoid Arthritis Therapeutics - Products under Development by Companies 38
Rheumatoid Arthritis Therapeutics - Products under Investigation by Universities/Institutes 62
Companies Involved in Rheumatoid Arthritis Therapeutics Development 63
Rheumatoid Arthritis - Therapeutics Assessment 264
Drug Profiles 271
Rheumatoid Arthritis Therapeutics - Drug Profile Updates 322
Rheumatoid Arthritis Therapeutics - Discontinued Products 352
Rheumatoid Arthritis Therapeutics - Dormant Products 358
Rheumatoid Arthritis - Product Development Milestones 374
Appendix 384

For more information open Rheumatoid Arthritis - Pipeline Review, H2 2013.

SKU: GMDHC3928IDB

Original Article: Rheumatoid Arthritis - Pipeline Review, H2 2013

NEXT ARTICLE

More From BioPortfolio on "Rheumatoid Arthritis - Pipeline Review, H2 2013"

Search BioPortfolio:
Advertisement

Relevant Topic

Orthopedics
Latest News Clinical Trials Research Drugs Reports Corporate
Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may involve operation, manipulation, traction or prostheses. (Oxford Medical Dictiona...

Advertisement

Searches Linking to this Story